ArticleChemical science2026
Invoking ferroptosis and photon-controlled pyroptosis
Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antitumor agents that rely solely on apoptosis often fail to disrupt the complementary cell survival cascades. In this study, we developed a redox-responsive integrated therapeutic system (QSH) that exploited ferroptosis and pyroptosis to enhance tumor therapy. QSH consisted of a dihydroorotate dehydrogenase (DHODH in mitochondria) inhibitor (Q, a ferroptosis inducer) and a photosensitiser (IHcy, a pyroptosis trigger) linked by a disulphide bond. Upon entering cancer cells, QSH could effectively target mitochondria by leveraging the mitochondrial membrane potential. Within the highly redox-stressed tumor microenvironment, the disulfide bonds were cleaved by glutathione (GSH), leading to the release of Q and IHcy, which promoted glutathione peroxidase 4 (GPX4)-mediated ferroptosis (the first pathway). The released Q inhibited DHODH activity within mitochondria, thereby disrupting the DHODH-mediated mitochondrial antioxidant system and also promoting ferroptosis (the second pathway). Under light irradiation, the photodynamic effect of IHcy triggered gasdermin D (GSDMD)-mediated pyroptosis (the third pathway), thereby promoting the release of damage-associated molecular patterns. Significantly, QSH completely suppressed tumor growth in 4T1 breast cancer models due to the synchronous activation of ferroptosis and pyroptosis in tumors. This redox-triggered triple-pathway strategy effectively elevated the level of lipid peroxidation within cells, induced immunogenic cell death, and enhanced tumor sensitivity to treatments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.